FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 01/2023”. The Monitor is a month-to-month printed overview of enterprise capital tendencies within the European Life Sciences sector.
As of the tip of January 2023 we establish the next present VC tendencies in Europe:
- In January 2023, general Life Sciences funding has reached EUR 567m
- High 5 Offers exceed EUR 25m every, largest transaction amounted to EUR 130m in Amolyt Pharma (France)
- Andera Companions (France) dominates the High 5 Traders (by deal quantity), adopted by Kurma Companions (France) and Gilde Healthcare Companions (Netherlands)
- Biotech acquired 49% of the whole funding quantity
- Metabolic Problems dominates as the highest indication in Biotechnology
- The financing quantity for Life Sciences in January 2023 is considerably decrease and makes up solely a 3rd of the financing quantity in January 2022
To entry the total report, please click on right here.
By Dr. Mathias Schott, Johannes Hyperlink and Marco Buonafede-Bennardo.